Profile data is unavailable for this security.
About the company
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
- Revenue in USD (TTM)0.00
- Net income in USD-240.16m
- Incorporated2020
- Employees130.00
- LocationACELYRIN Inc4149 Liberty Canyon RoadAGOURA HILLS 91301United StatesUSA
- Phone+1 (805) 730-0360
- Fax+1 (302) 655-5049
- Websitehttps://www.acelyrin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | 6.48m | -190.05m | 388.17m | 181.00 | -- | 0.9107 | -- | 59.92 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Absci Corp | 5.35m | -109.19m | 393.53m | 155.00 | -- | 1.64 | -- | 73.60 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Neurogene Inc | 0.00 | -39.03m | 393.56m | 91.00 | -- | 2.28 | -- | -- | -4.58 | -4.58 | 0.00 | 13.28 | 0.00 | -- | -- | 0.00 | -26.57 | -32.70 | -28.41 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Precigen Inc | 5.44m | -96.91m | 396.30m | 202.00 | -- | 4.05 | -- | 72.86 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Tourmaline Bio Inc | 0.00 | -32.94m | 398.80m | 44.00 | -- | 1.13 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -76.87m | 403.11m | 118.00 | -- | 1.82 | -- | -- | -1.73 | -1.73 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -44.70 | -33.76 | -48.55 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 2.51m | -99.43m | 403.38m | 76.00 | -- | 1.89 | -- | 160.71 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| AC Immune SA | 16.74m | -61.73m | 403.69m | 133.00 | -- | 2.47 | -- | 24.12 | -0.6923 | -0.6923 | 0.1884 | 1.65 | 0.088 | -- | 61.04 | 125,860.30 | -32.45 | -18.25 | -35.04 | -19.52 | -- | -- | -368.77 | -148.29 | -- | -- | 0.0225 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Alector Inc | 96.41m | -120.61m | 410.60m | 244.00 | -- | 2.30 | -- | 4.26 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 412.41m | 99.00 | -- | 2.01 | -- | 6.70 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Editas Medicine Inc | 69.41m | -166.13m | 414.48m | 265.00 | -- | 1.41 | -- | 5.97 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| ACELYRIN Inc | 0.00 | -240.16m | 415.91m | 130.00 | -- | 0.6447 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Altimmune Inc | 410.00k | -92.77m | 419.03m | 59.00 | -- | 2.42 | -- | 1,022.03 | -1.59 | -1.59 | 0.007 | 2.44 | 0.0022 | -- | 1.47 | 6,949.15 | -49.42 | -39.62 | -53.14 | -42.58 | -- | -- | -22,626.10 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| IGM Biosciences Inc | 2.11m | -236.92m | 427.33m | 216.00 | -- | 2.65 | -- | 203.01 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Verve Therapeutics Inc | 16.05m | -196.83m | 428.22m | 255.00 | -- | 0.7332 | -- | 26.68 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -129.44m | 439.69m | 186.00 | -- | 1.70 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
Data as of Jun 20 2024. Currency figures normalised to ACELYRIN Inc's reporting currency: US Dollar USD
50.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AyurMaya Capital Management Co. LPas of 31 Mar 2024 | 9.33m | 9.43% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.08m | 7.15% |
| Citadel Advisors LLCas of 31 Mar 2024 | 6.90m | 6.97% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.16m | 6.22% |
| Millennium Management LLCas of 08 May 2024 | 5.04m | 5.09% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.39m | 4.43% |
| Adage Capital Management LPas of 31 Mar 2024 | 3.28m | 3.31% |
| Tybourne Capital Management (HK) Ltd.as of 31 Mar 2024 | 2.91m | 2.94% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 2.41m | 2.43% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 2.18m | 2.20% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
